Literature DB >> 6496524

Cost containment associated with decreased parenteral antibiotic administration frequencies.

D J Tanner, M Q Nazarian.   

Abstract

Multi-region time and motion studies were conducted in hospitals of various sizes to determine the cost of personnel and supplies associated with the preparation, dispensing, and administration of reconstituted parenteral antibiotics. The administration systems studied included the piggyback intravenous admixture (including several batch methodologies), the volume control intravenous set, and intramuscular techniques. Supply costs were calculated for each system. Projections of potential cost savings resulting from decreased administrations of parenteral cephalosporins were calculated for surgical prophylaxis, 10-day treatment course, and average per bed hospital use. The projected cost savings for the first 24 hours of surgical prophylaxis, or a 10-day treatment course changing from every eight- to six-hour dosing to a single daily dose ranged from $5.60 to $24.25 and $28 to $145, respectively. The average hospital's projected cost savings potential per hospital bed resulting from decreased administration of parenteral cephalosporins depended on the administration system or systems used and ranged from $35 (25 percent reduction in doses) to $364 (75 percent reduction in doses). An algorithm is presented for individual hospitals to use in calculating cost containment estimates. Clinicians and health care managers should seriously consider the cost containment advantages provided by the substitution of newer antibiotics which permit reduced administration frequency.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6496524

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  11 in total

1.  Direct costs of intravenous delivery systems.

Authors:  S W Birdwell
Journal:  Pharmacoeconomics       Date:  1993-07       Impact factor: 4.981

2.  What you should know about HSOs.

Authors:  D Peachey; A Linton
Journal:  CMAJ       Date:  1988-02-15       Impact factor: 8.262

3.  Defining criteria for the pharmacoeconomic evaluation of new oral cephalosporins.

Authors:  P G Davey; M Malek
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

Review 4.  Antimicrobial therapy. Cost-benefit considerations.

Authors:  B J Guglielmo; G F Brooks
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

5.  Those golden years.

Authors:  D Waugh
Journal:  CMAJ       Date:  1987-08-01       Impact factor: 8.262

6.  Computer modelling antibiotic therapy costs. Impact of therapeutic range.

Authors:  H E Gladen
Journal:  Drugs       Date:  1988       Impact factor: 9.546

7.  Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  R Davis; H M Bryson
Journal:  Pharmacoeconomics       Date:  1994-09       Impact factor: 4.981

Review 8.  Once-daily aminoglycoside administration in gram-negative sepsis. Economic and practical aspects.

Authors:  S E Parker; P G Davey
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

9.  Cost of gentamicin assays carried out by microbiology laboratories.

Authors:  P F Vacani; M M Malek; P G Davey
Journal:  J Clin Pathol       Date:  1993-10       Impact factor: 3.411

Review 10.  Use of teicoplanin in community medicine.

Authors:  A P Wilson; R N Grüneberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-09       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.